Wilson Martin 4
4 · ROCKET PHARMACEUTICALS, INC. · Filed Feb 18, 2026
Research Summary
AI-generated summary of this filing
Rocket Pharmaceuticals GC Martin Wilson Sells 12,253 Shares
What Happened
Martin Wilson, General Counsel of Rocket Pharmaceuticals (RCKT), sold 12,253 shares of common stock on February 13, 2026 at $3.31 per share, generating approximately $40,582 in proceeds. The filing reports this as a sale (S), not a purchase.
Key Details
- Transaction date: 2026-02-13; price: $3.31; shares sold: 12,253; proceeds: ~$40,582.
- Transaction type: Sale (open market or private sale). Reported reason (F2): shares sold to pay tax withholding obligations in connection with RSU vesting.
- Holdings note (F1): reported holdings include Restricted Stock Units (RSUs) that convert 1-for-1 into common stock.
- Filing date: 2026-02-18. Form 4s must be filed within two business days; this filing appears timely (Feb 18), with Feb 16 being a federal holiday.
Context
The sale was executed to cover taxes on vested RSUs (routine tax-withholding sale) rather than a discretionary stock sale for investment reasons. Such withholding sales are common and typically do not, by themselves, indicate insider sentiment about the company’s prospects. For a fuller picture, review the full Form 4 for post-transaction holdings and monitor future insider buys or sells.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-02-13$3.31/sh−12,253$40,582→ 683,376 total
Footnotes (2)
- [F1]Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
- [F2]The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.